Johnson & Johnson Aktie News

These companies have resilient businesses that can navigate challenges. Both are great dividend-paying stocks.

Johnson & Johnson NYSE: JNJ, amid the noise of Trump's Greenland agenda and renewed trade war fears, is quietly executing its healthcare strategy, growing revenue and widening margins, setting its stock up to continue trending higher. A recent earnings release and 2026 guidance update, though strong, triggered a price pullback and a trend-following opportunity.

Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest U.S.

Johnson & Johnson has increased its dividend for an impressive 63 consecutive years. The company appears to be navigating an expanding patent cliff well.

Johnson & Johnson has increased its dividend each year for over half a century. The company has a very healthy financial profile.

PENSACOLA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- A U.S. District Court Special Master in the talc multidistrict litigation (MDL) against Johnson & Johnson (J&J) entered an Opinion, reaffirming that plaintiffs may present expert testimony supporting general causation to the jury.

Johnson & Johnson signed a deal to avoid tariffs. Although it faces other threats, it can overcome them.

Johnson & Johnson's MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release. The segment slightly outpaced the healthcare solution provider's other segment, Innovative Medicine, whose worldwide operational sales were up 5.